The researchers said that due to its amphiphilic nature, the AmB has poor aqueous solubility and forms aggregates in the system, which stresses renal filtration and thus causing nephrotoxicity (adverse impact of medicines on the kidney).
Since the main concern with high drug loading was nephrotoxicity, the team has carried out a cell viability assay (MTT assay) against human kidney fibroblast cells which illustrated no evidence of cell toxicity caused by AmB, the institute said.
Dr. Chandra Shekhar Sharma, Associate Professor, Department of Chemical Engineering Sharma said that since the idea behind the research was to find a solution to serve society, the oral solution developed is made free from intellectual property so that it can be mass produced and is made affordable and available to all.
The 60 mg AmB tablet will be affordable at Rs. 200 and is patient-friendly ensuring its slow and steady release thus reducing nephrotoxicity.
The research team has also explained the concept in a video on YouTube.